Patent: 9,345,766
✉ Email this page to a colleague
Summary for Patent: 9,345,766
| Title: | Combination therapies comprising anti-ERBB3 agents |
| Abstract: | Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof; and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof. |
| Inventor(s): | Zhang; Bo (Lynnfield, MA), McDonagh; Charlotte (Winchester, MA), Huhalov; Alexandra (Cambridge, MA) |
| Assignee: | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 14/015,776 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,345,766
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-08-30 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-08-30 |
| Genentech, Inc. | KADCYLA | ado-trastuzumab emtansine | For Injection | 125427 | 02/22/2013 | ⤷ Try a Trial | 2032-08-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
